Patents · October 19, 2026
How Do Pharmaceutical Companies Protect New Drug Formulations and Delivery Methods in Irvine, CA?
Pharmaceutical companies protect new drug formulations and delivery methods with layered patents covering the composition, method of use, dosing regimen, and manufacturing process, often backed by trade secrets for know-how. A formulation patent must be new and non-obvious, and only some patent types qualify for FDA Orange Book listing. Learn how patent prosecution works or explore patent law in Irvine, CA.
What Is a Formulation Patent and How Does It Protect a Drug Product?
A formulation patent protects a specific composition of a drug product, such as the mix of active ingredient, excipients, concentrations, and release profile, rather than the active molecule itself. FDA’s Orange Book regulations call these drug product patents, meaning patents that claim the formulation or composition. For a company in Irvine, CA, or elsewhere in Orange County, this matters because the compound patent on a molecule may expire or belong to someone else, while a new extended-release tablet, injectable suspension, or pediatric liquid may still qualify for its own protection. Like other utility patents, a formulation patent generally lasts 20 years from its earliest U.S. nonprovisional filing date, subject to adjustments. It must also meet the novelty, non-obviousness, and written description requirements of the Patent Act before the USPTO will grant it.
What Types of Pharmaceutical Patents Can Cover a Single Drug?
Most marketed drugs are protected by a portfolio of patents rather than a single filing, and each type covers a different part of the product. Layering these filings can extend a company’s practical protection beyond the original compound patent, as long as each one meets patentability standards on its own. Federal regulations at 21 C.F.R. 314.53 sort listable patents into drug substance, drug product, and method-of-use categories, while other types stay out of the Orange Book but can still be enforced in court. A typical portfolio for a new delivery technology may include several of the categories below, each drafted and timed around clinical data. Planning the order of filings early also helps keep your own publications, conference posters, or clinical disclosures from being used as prior art against later applications.
- Compound (drug substance) patents on the active molecule
- Formulation (drug product) patents on the composition, excipients, and release profile
- Method-of-use and dosage regimen patents on treating a condition at a set dose or schedule
- Process patents on manufacturing steps, which cannot be listed in the Orange Book
- Polymorph and salt patents on specific crystalline forms of the active ingredient
- Delivery device patents on inhalers, autoinjectors, and similar hardware
Why Are Formulation Patents Often Challenged as Obvious?
Obviousness is the most common hurdle for formulation patents, because examiners and challengers often view a new combination of known excipients as a predictable variation. In KSR International Co. v. Teleflex Inc., decided April 30, 2007, the Supreme Court rejected a rigid test for obviousness and explained that combining familiar elements by known methods is likely obvious when it yields predictable results. The Court also said an approach can be obvious to try when there are a finite number of identified, predictable solutions. For drug companies, this means the application should document unexpected results, such as improved stability, bioavailability, or tolerability, with comparative data. Generic companies rely on the same reasoning in litigation, so a formulation claim supported by thin data may be granted by the USPTO and later invalidated in court.
Which Formulation and Delivery Patents Can Be Listed in the Orange Book?
Under 21 C.F.R. 314.53, NDA holders must submit drug substance, drug product (formulation and composition), and method-of-use patents for Orange Book listing, while process, packaging, metabolite, and intermediate patents must not be submitted. Listing matters because a listed patent can trigger the generic challenge process and a possible 30-month stay on approval. The Federal Trade Commission has focused on device patents listed for drug products. On November 7, 2023, the FTC challenged more than 100 patents listed for products such as inhalers and autoinjectors, and in May 2025 it renewed challenges to more than 200 listings. In Teva v. Amneal, decided December 20, 2024, the Federal Circuit held that a listed patent must claim at least the active ingredient, so patents claiming only device components do not qualify.
How Do Generic Drug Companies Challenge Formulation Patents?
A generic company typically challenges a listed formulation patent by filing an abbreviated new drug application with a Paragraph IV certification stating that the patent is invalid, unenforceable, or will not be infringed. According to FDA, if the brand company or patent owner sues within 45 days of receiving notice, approval of the generic is generally postponed for 30 months, unless the patent expires or is found invalid or not infringed sooner. The first applicant with a substantially complete application containing a Paragraph IV certification is generally eligible for 180 days of generic exclusivity. Because generic firms often design around formulation claims by changing excipients or particle size, claim breadth and supported ranges matter. Patents also interact with separate FDA protections, explained in our guide to patent vs. FDA exclusivity.
When Should a California Drug Company Use Trade Secrets Instead of Patents?
Trade secrets can make sense for manufacturing know-how that competitors cannot easily reverse engineer from the finished product, such as process parameters, equipment settings, or supplier specifications. California’s Uniform Trade Secrets Act, Civil Code section 3426 and following, protects information that has independent economic value from not being generally known and that is subject to reasonable efforts to keep it secret. The federal Defend Trade Secrets Act, 18 U.S.C. 1836, adds a civil claim in federal court. Unlike a patent, a trade secret does not expire on a fixed date, but it offers no protection against independent development or reverse engineering. Because a drug’s composition is usually disclosed on its label and in FDA filings, the formulation itself is often better suited to patents, while the method of making it may stay confidential.
Where Can You Get Help With a Formulation Patent in Irvine, CA?
Help with a formulation patent in Irvine, CA usually starts with a review of your data, prior art, and regulatory timeline before anything is published or presented. mjIP is an Irvine intellectual property law firm founded in 2010 by a USPTO-registered patent attorney with a biology degree and prior in-house experience at a Fortune 500 pharmaceutical company in Orange County. The firm assists biotech, pharmaceutical, and supplement companies with patent prosecution in Irvine, CA, including provisional and utility applications for new formulations and delivery methods. Fees are discussed during a free consultation. To schedule one, contact the firm or call (949) 833-7125. This article is general information, not legal advice, and reading it does not create an attorney-client relationship.
Common Questions
Frequently Asked Questions About Formulation Patents in Irvine, CA
A formulation patent claims a specific composition of a drug product, such as the active ingredient combined with particular excipients, concentrations, or a release mechanism. FDA regulations treat it as a drug product patent that can be listed in the Orange Book if it covers the approved product. It is separate from the compound patent on the molecule and can be filed years later, as long as the new formulation is novel and non-obvious.
Yes, a new formulation of a known drug can be patented if it is novel, non-obvious, and adequately described. The challenge is obviousness, because combining known excipients by known methods can be considered predictable under the Supreme Court’s KSR decision. Applicants usually need comparative data showing unexpected results, such as better stability, absorption, or patient tolerability, to support the claims during examination and in any later challenge.
A formulation patent generally lasts 20 years from the earliest U.S. nonprovisional filing date it claims, subject to patent term adjustment for USPTO delays and terminal disclaimers. Because formulation patents are often filed after the compound patent, they may expire later. A patent term extension under 35 U.S.C. 156 is limited to one patent per regulatory review period, so it is often used on the compound patent instead.
Only if the patent claims the drug. In Teva v. Amneal, decided December 20, 2024, the Federal Circuit held that a listed patent must claim at least the active ingredient, so patents claiming only device components do not qualify. The FTC has also challenged hundreds of device patent listings since November 2023, so companies should review listing decisions carefully with counsel.
A Paragraph IV challenge is a certification in a generic drug application stating that a listed patent is invalid, unenforceable, or will not be infringed. If the patent owner sues within 45 days of notice, FDA approval is generally postponed for 30 months. The first qualifying generic filer may be eligible for 180 days of marketing exclusivity, which gives generic companies a strong incentive to challenge weak formulation patents.
It depends on whether the process can be discovered from the finished product or from regulatory filings. Process patents cannot be listed in the Orange Book but can still be enforced in court. A trade secret can last as long as it stays confidential under California and federal law, yet it offers no protection if a competitor develops the same process independently or reverse engineers it.